Project Grant R43HG011877
- Micropure Genomics Inc. received a $274,199 Project Grant award from the National Science Foundation to advance methods for rapid, end-to-end sample preparation for sequencing applications. Under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the company will develop an automated process relying on electro-hydrodynamic trapping to isolate genomic material like DNA or RNA from cells in a flow cartridge. The process aims to significantly reduce preparation time while...
- This $256,000 National Science Foundation Engineering grant supports the development of an easy RNA adenylation method for deep sequencing of picogram RNA samples with high resolution. Specifically, Ezrabio Inc. will develop a versatile and cost-effective library construction technology that enables protein translation monitoring on a variety of biological samples. The proposed technology relies on a novel enzyme system capable of 5' adenylation and 3' polyadenylation of RNA fragments to...
- FIND-SEQ Cell Sorting Technology Development and Commercialization The National Institute on Aging awarded Vivid Bioinnovations, PBC (operating as Fluid Discovery, Inc.) a $613,742 Project Grant under the Aging Research program (CFDA 93.866) on September 12, 2025, with a completion date of February 28, 2027. This Fast-Track Small Business Innovation Research (SBIR) award supports the translation and commercial development of FIND-SEQ, a novel cell sorting technology that enables isolation of...
- Sequegenics LLC received a $251,073 Project Grant award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041). The grant supports development of low-cost and scalable methods for creating genomic databases using long-read next-generation DNA sequencing technologies. This aligns with the program's goals of fostering innovation in engineering research. The one-year project period runs from August 1, 2021 through July 31,...
- The Bigelow Laboratory for Ocean Sciences will develop a novel microencapsulation-based technology for whole genome sequencing of RNA viruses from ocean environments under a two-year, $599,048 Project Grant from the National Science Foundation Division of Ocean Sciences' Geosciences program (CFDA 47.050). The laboratory aims to address the pressing need for direct quantification methods for small RNA viruses in marine samples, which play a major role in microbial ecology and evolution but are...
- New York University School of Medicine received a $703,227 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded June 1, 2026, with a completion date of May 31, 2031. The grant supports development of an ultra-rapid droplet digital polymerase chain reaction (ddPCR) technology platform designed to deliver molecular-genetic profiling of cancer-driving mutations directly within the operating room during surgical resection...
- The Alida Biosciences Inc. was awarded a $765,105 Project Grant from the National Institutes of Health National Human Genome Research Institute under the Human Genome Research federal grant program (CFDA 93.172) on August 17, 2021 to complete work by February 28, 2022. The grant funds the development of a new approach to analyze RNA modifications across entire transcriptomes in a multiplexed reaction at near single-base resolution. Currently available methods either lack sequence context or...
- The National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), awarded a $384,418 Project Grant to Xgenomes Corp. on September 25, 2024 to develop a revolutionary DNA sequencing platform. The project aims to create a super-resolution single-molecule sequencing technology that can read short sequence "words" rather than individual nucleotides, enabling one or more orders of magnitude improvements in accuracy and cost over...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
- This National Science Foundation (NSF) Project Grant, awarded under the Biological Sciences program (CFDA 47.074), provides $750,000 to Stanford University to develop new technologies for studying RNA, the essential molecules that carry genetic information and play crucial roles in cell functions. The key products and services to be delivered under this 3-year award include: Creating non-destructive methods to directly study RNA localization and interactions within living cells, achieving...
A SINGLE-STRAND LIGATION APPROACH FOR CONCOMITANT DNA AND RNA NEXT-GENERATION SEQUENCING FROM LOW ABUNDANCE INPUTS - PROJECT SUMMARY INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSES CAPTURE A WEALTH OF INFORMATION THAT CAN IMPROVE OUR UNDERSTANDING OF NORMAL BIOLOGICAL PHENOMENA AND DISEASE. COMBINING DNA AND RNA NEXT-GENERATION SEQUENCING (NGS) DATA FROM THE SAME SAMPLE CAN IMPROVE PREDICTIVE POWER OF DIAGNOSTIC AND PROGNOSTIC ASSAYS. HOWEVER, PERFORMING MULTIOMIC ANALYSES IS OFTEN NOT FEASIBLE DUE TO LIMITED SAMPLE AVAILABILITY OR LOW NUCLEIC ACID YIELDS ESPECIALLY IN SINGLE-CELLS AND LIQUID BIOPSIES. EXTRACELLULAR NUCLEIC ACIDS DERIVED FROM LIQUID BIOPSIES SUCH AS PLASMA, URINE AND CEREBROSPINAL FLUID ARE INCREASINGLY USED FOR RAPID AND NON-INVASIVE DISEASE DETECTION AND TREATMENT RESPONSE MONITORING IN CANCER AND INFECTIOUS DISEASES. AN INTEGRATED PROTOCOL THAT CAPTURES BOTH DNA AND RNA CAN BE OF TREMENDOUS VALUE IN LIQUID BIOPSY-BASED DIAGNOSTICS BY SAVING PRECIOUS CLINICAL SAMPLES AND REDUCING REAGENTS REQUIREMENT AND SEQUENCING COSTS. TRADITIONAL NGS LIBRARY PREPARATION METHODS FOR DNA AND RNA HAVE SOME OVERLAP IN PROTOCOL AND TYPICALLY UTILIZE A COMMON SEQUENCING PLATFORM. HOWEVER, THESE METHODS ARE CANNOT BE ADAPTED FOR SIMULTANEOUS LIBRARY GENERATION DUE TO SUBSTRATE AND ENZYMATIC LIMITATIONS. IN CONTRAST, CLARET BIOSCIENCE'S INNOVATIVE SINGLE-STRAND LIGATION APPROACH FACILITATES DIRECT LIBRARY PREPARATION FROM BOTH RNA AND DNA IN THREE SIMPLIFIED STEPS. THE METHOD ALSO ADDS NUCLEIC ACID-SPECIFIC MOLECULAR BARCODES WHICH ENABLE IN SILICO DECONVOLUTION OF DNA AND RNA-DERIVED SEQUENCES, MAKING THIS METHOD IDEAL FOR COMPREHENSIVE NGS ANALYSES. IN THIS PROPOSAL, WE SEEK TO DEVELOP AND OPTIMIZE A CONCOMITANT DNA AND RNA NGS LIBRARY PREPARATION PROTOCOL USING A CONTRIVED MIXTURE OF FRAGMENTED HUMAN GENOMIC DNA AND YEAST RNA ALONG WITH SPIKE-IN CONTROLS (WHICH SERVE AS "GROUND TRUTH") AS INPUT. WE WILL PERFORM A SERIES OF EXPERIMENTS TO TEST THE EFFICACY OF THE PROTOCOL USING A RANGE OF INPUT AMOUNT AND VARIABLE RATIOS OF DNA AND RNA TO MIMIC THE COMPOSITIONS FREQUENTLY ENCOUNTERED IN CLINICAL SAMPLES. WE WILL EVALUATE THE STRINGENCY OF ADAPTER LIGATION USING THE NUCLEIC ACID-SPECIFIC BARCODE AND GENERATE A USER-FRIENDLY BIOINFORMATIC PIPELINE THAT WILL ULTIMATELY ACCOMPANY THE ASSAY, FOR EASY BIOINFORMATIC EXTRACTION OF GENOMIC AND TRANSCRIPTOMIC DATA FROM A GIVEN LIBRARY. TO EVALUATE PROTOCOL PERFORMANCE, WE DETERMINE IF THE MOLECULAR, SEQUENCING AND MAPPING METRICS OF OUR METHOD ARE EQUIVALENT TO THE METRICS OBTAINED WITH INDIVIDUAL LIBRARY PREPARATION PROTOCOLS, FOR BOTH DNA AND RNA. FINALLY, WE WILL DEMONSTRATE BIOLOGICAL UTILITY OF THE METHOD USING OUR IN-HOUSE REPOSITORY OF CELL-FREE NUCLEIC ACIDS DERIVED FROM HEALTHY PLASMA SAMPLES. SUCCESSFUL ACCOMPLISHMENT OF THESE AIMS WILL GENERATE A ROBUST ASSAY THAT SIMULTANEOUSLY GENERATES DNA AND RNA NGS LIBRARIES WITHIN FOUR HOURS. WHEN COMBINED WITH MINIMALLY INVASIVE LIQUID BIOPSY-BASED APPROACHES, THE COMBINATORIAL NGS ASSAY DESCRIBED HERE CAN SIGNIFICANTLY REDUCE FINANCIAL AND PHYSICAL BURDEN ON THE PATIENT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 5/10/23 | ||
| Not listed | $224.4k | 9/6/21 | ||
| Not listed | $224.4k | 9/6/21 |